{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:54:30Z","timestamp":1761947670000},"reference-count":36,"publisher":"BMJ","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Ethics"],"accepted":{"date-parts":[[2010,10,4]]},"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:sec><jats:title>Background\/Aims<\/jats:title><jats:p>Mucopolysaccharidosis type I (MPS I) is a rare lysosomal storage disorder treated with bone marrow transplantation or enzyme replacement therapy with laronidase, a high-cost orphan drug. Laronidase was approved by the US Food and Drug Administration and the European Medicines Agency in 2003 and by the Brazilian National Health Surveillance Agency in 2005. Many Brazilian MPS I patients have been receiving laronidase despite the absence of a governmental policy regulating access to the drug. Epidemiological and treatment data concerning MPS I are scarce. This study aims to present a demographic profile of Brazilian patients with MPS I, describe the routes of access to laronidase in Brazil, and discuss associated ethical issues relating to public funding of orphan drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this cross-sectional observational study, data were collected nationwide between January and September 2008 from physicians, public institutions and non-governmental organisations involved with diagnosis and treatment of MPS I, using two data collection instruments specifically designed for this purpose.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The minimum prevalence of MPS I in Brazil was estimated at 1\/2\u2008700\u2008000. Most patients (69.8%) were younger than 15\u2005years; 60 (88.2%) received laronidase. The most common route of access to the drug was through lawsuits (86.6%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In Brazil, MPS I is predominantly a paediatric illness. Even though the cost of laronidase treatment is not officially covered by the Brazilian government, most MPS I patients receive the drug, usually through litigation. This gives rise to major ethical conflicts concerning drug access in a low-resource context. The Brazilian health policy framework lacks evidence-based clinical protocols for the distribution of orphan drugs.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jme.2010.037150","type":"journal-article","created":{"date-parts":[[2011,1,26]],"date-time":"2011-01-26T01:36:10Z","timestamp":1296005770000},"page":"233-239","source":"Crossref","is-referenced-by-count":14,"title":["Ethical issues related to the access to orphan drugs in Brazil: the case of mucopolysaccharidosis type I"],"prefix":"10.1136","volume":"37","author":[{"given":"Raquel","family":"Boy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida V D","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e1rbara C","family":"Krug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz C","family":"Santana-da-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos E","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelina X","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erlane M","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcial F","family":"Galera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo G C","family":"Leivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlene","family":"Braz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2011,1,25]]},"reference":[{"key":"2024052301202554000_37.4.233.1","unstructured":"Neufeld E Muenzer J . The mucopolysaccharidosis. In: Scriver CR Beaudet AL Sly S , eds. The metabolic and molecular basis of inherited disease. 7th edn. New York, NY: McGraw-Hill, 2001:3421\u00e2\u0080\u009352."},{"key":"2024052301202554000_37.4.233.2","first-page":"41","article-title":"Newborn screening for lysosomal storage: current issues and approaches","volume":"5","author":"Meikle","year":"2005","journal-title":"Curr Med Literature"},{"key":"2024052301202554000_37.4.233.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02654.x"},{"key":"2024052301202554000_37.4.233.4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705988"},{"key":"2024052301202554000_37.4.233.5","first-page":"36","article-title":"Drugs for rare diseases: mixed assessment in Europe","volume":"16","year":"2007","journal-title":"Prescrire Int"},{"key":"2024052301202554000_37.4.233.6","unstructured":"US Food and Drug Administration (FDA). Developing products for rare diseases and conditions. http:\/\/www.fda.gov\/orphan\/index.htm (accessed 15 Dec 2007)."},{"key":"2024052301202554000_37.4.233.7","unstructured":"European Medicines Agency (EMA). European Medicines Agency (EMA). Rare disease designation \u00e2\u0080\u0093 Laronidase. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/orphans\/2009\/11\/human_orphan_000050.jsp&murl=menus\/medicines\/medicines.jsp&mid=WC0b01ac058001d12b (accessed 13 Jan 2011)."},{"key":"2024052301202554000_37.4.233.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2004.01.046"},{"key":"2024052301202554000_37.4.233.9","unstructured":"Schwartz I Martins TF Federhen A . A Rede MPS faz quatro anos: um panorama geral sobre a epidemiologia das MPS no Brasil. In: Anais do XX Congresso Brasileiro de Gen\u00c3\u00a9tica M\u00c3\u00a9dica, 2008:21. Sociedade Brasileira de Gen\u00c3\u00a9tica M\u00c3\u00a9dica. Serrano Centro de Conven\u00c3\u00a7\u00c3\u00b5es, Gramado, RS, Brazil. 28 to 31 May 2008."},{"key":"2024052301202554000_37.4.233.10","unstructured":"Ag\u00c3\u00aancia Nacional de Vigil\u00c3\u00a2ncia Sanit\u00c3\u00a1ria (ANVISA). Gloss\u00c3\u00a1rio da Anvisa. Brazil. http:\/\/e-glossario.bvs.br\/glossary\/public\/scripts\/php\/page_search.php?lang=&letter=M (accessed 15 Dec 2007)."},{"key":"2024052301202554000_37.4.233.11","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1590\/S1020-49892008000300007","article-title":"O uso de drogas ainda experimentais em assist\u00c3\u00aancia: extens\u00c3\u00a3o de pesquisa, uso compassivo e acesso expandido","volume":"23","author":"Goldim","year":"2008","journal-title":"Rev Panam Salud Publica"},{"key":"2024052301202554000_37.4.233.12","unstructured":"Horovitz DD . Aten\u00c3\u00a7\u00c3\u00a3o aos defeitos cong\u00c3\u00aanitos no Brasil: proposta para estrutura\u00c3\u00a7\u00c3\u00a3o e integra\u00c3\u00a7\u00c3\u00a3o da abordagem no sistema de sa\u00c3\u00bade [dissertation]. Rio de Janeiro, Brazil: Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro. 2003."},{"key":"2024052301202554000_37.4.233.13","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.32320"},{"key":"2024052301202554000_37.4.233.14","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-3-24"},{"key":"2024052301202554000_37.4.233.15","unstructured":"Instituto Brasileiro de Geografia e Estat\u00c3\u00adtica (IBGE). Contagem da popula\u00c3\u00a7\u00c3\u00a3o. Brazil, 2007. http:\/\/www.ibge.gov.br\/home\/estatistica\/populacao\/contagem2007\/contagem.pdf (accessed Jan 2009)."},{"key":"2024052301202554000_37.4.233.16","doi-asserted-by":"publisher","DOI":"10.1136\/jme.2003.007138"},{"key":"2024052301202554000_37.4.233.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2006.01.010"},{"key":"2024052301202554000_37.4.233.18","first-page":"iii","article-title":"A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies of Fabry's disease and mucopolysaccharidosis type I","volume":"10","author":"Connock","year":"2006","journal-title":"Health Technol Assess"},{"key":"2024052301202554000_37.4.233.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2007.01.011"},{"key":"2024052301202554000_37.4.233.20","unstructured":"Constitui\u00c3\u00a7\u00c3\u00a3o da Rep\u00c3\u00bablica Federativa do Brasil. T\u00c3\u00adtulo VIII, cap\u00c3\u00adtulo II, se\u00c3\u00a7\u00c3\u00a3o II, \u00e2\u0080\u009cDa Sa\u00c3\u00bade\u00e2\u0080\u009d (1988). http:\/\/www.planalto.gov.br\/ccivil_03\/constituicao\/constitui%C3%A7ao.htm (accessed 12 Jan 2011)."},{"key":"2024052301202554000_37.4.233.21","unstructured":"Tocqueville A . A democracia na Am\u00c3\u00a9rica. S\u00c3\u00a3o Paulo: Abril, 1985:240."},{"key":"2024052301202554000_37.4.233.22","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1590\/S0034-89102007000200007","article-title":"Distor\u00c3\u00a7\u00c3\u00b5es causadas pelas a\u00c3\u00a7\u00c3\u00b5es judiciais \u00c3\u00a0 pol\u00c3\u00adtica de medicamentos no Brasil","volume":"41","author":"Vieira","year":"2007","journal-title":"Rev Saude Publica"},{"key":"2024052301202554000_37.4.233.23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1590\/S0034-89102008000200025","article-title":"A\u00c3\u00a7\u00c3\u00b5es judiciais e direito \u00c3\u00a0 sa\u00c3\u00bade: reflex\u00c3\u00a3o sobre a observ\u00c3\u00a2ncia aos princ\u00c3\u00adpios do SUS","volume":"42","author":"Vieira","year":"2008","journal-title":"Rev Saude Publica"},{"key":"2024052301202554000_37.4.233.24","unstructured":"Ag\u00c3\u00aancia Nacional de Vigil\u00c3\u00a2ncia Sanit\u00c3\u00a1ria (ANVISA), Brazil. Resolu\u00c3\u00a7\u00c3\u00a3o n\u00c2\u00b0 16, de 13 de mar\u00c3\u00a7o de 2008. Di\u00c3\u00a1rio Oficial da Uni\u00c3\u00a3o 2008;I:38."},{"key":"2024052301202554000_37.4.233.25","first-page":"iii","article-title":"The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review","volume":"10","author":"Connock","year":"2006","journal-title":"Health Technol Assess"},{"key":"2024052301202554000_37.4.233.26","unstructured":"Picon P Prolla P Amaral K . Doen\u00c3\u00a7a de Gaucher. In: Picon P Beltrame A , eds. Protocolos cl\u00c3\u00adnicos e diretrizes terap\u00c3\u00aauticas. Bras\u00c3\u00adlia: Minist\u00c3\u00a9rio da Sa\u00c3\u00bade, 2002:217\u00e2\u0080\u009334."},{"key":"2024052301202554000_37.4.233.27","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-2156"},{"key":"2024052301202554000_37.4.233.28","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200519010-00001"},{"key":"2024052301202554000_37.4.233.29","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-3847"},{"key":"2024052301202554000_37.4.233.30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1017\/S0266462307051550","article-title":"Assessing the economic challenges posed by orphan drugs","volume":"23","author":"Drummond","year":"2007","journal-title":"Int J Technol Assess Health Care"},{"key":"2024052301202554000_37.4.233.31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5694\/j.1326-5377.2008.tb01500.x","article-title":"Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand","volume":"188","author":"Raftery","year":"2008","journal-title":"Med J Aust"},{"key":"2024052301202554000_37.4.233.32","unstructured":"Beauchamp TL Childress JF . Beneficence. In: Beauchamp TL Childress JF , eds. Principles of biomedical ethics. Oxford: Oxford University Press, 2001:165\u00e2\u0080\u0093224."},{"key":"2024052301202554000_37.4.233.33","unstructured":"Rawls J . Uma teoria da justi\u00c3\u00a7a. S\u00c3\u00a3o Paulo: Martins Fontes, 1997."},{"key":"2024052301202554000_37.4.233.34","doi-asserted-by":"crossref","unstructured":"Daniels N . Justice and justification: reflexive equilibrium in theory and practice. New York: Cambridge University Press, 1996.","DOI":"10.1017\/CBO9780511624988"},{"key":"2024052301202554000_37.4.233.35","unstructured":"Sen A . Desenvolvimento como Liberdade. S\u00c3\u00a3o Paulo: Companhia das Letras, 2000:10."},{"key":"2024052301202554000_37.4.233.36","unstructured":"Singer P . Vida \u00c3\u0089tica. Rio de Janeiro, Brazil: Ediouro, 2002."}],"container-title":["Journal of Medical Ethics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jme.2010.037150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T10:20:50Z","timestamp":1716459650000},"score":1,"resource":{"primary":{"URL":"https:\/\/jme.bmj.com\/lookup\/doi\/10.1136\/jme.2010.037150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,25]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2011,3,17]]},"published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1136\/jme.2010.037150"],"URL":"https:\/\/doi.org\/10.1136\/jme.2010.037150","relation":{},"ISSN":["0306-6800","1473-4257"],"issn-type":[{"value":"0306-6800","type":"print"},{"value":"1473-4257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,25]]}}}